Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37316442)

  • 1. [Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].
    Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
    Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):325-337. PubMed ID: 37316442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Hu M; Zhong C; Wang J; Chen J; Zhou T
    Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
    Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
    Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
    Ou SI; Hong JL; Christopoulos P; Lin HM; Vincent S; Churchill EN; Soeda J; Kazdal D; Stenzinger A; Thomas M
    J Thorac Oncol; 2023 Jun; 18(6):744-754. PubMed ID: 36738930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
    Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
    Bai Q; Wang J; Zhou X
    Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
    Liu J; Xiang Y; Fang T; Zeng L; Sun A; Lin Y; Lu K
    Clin Lung Cancer; 2024 Mar; 25(2):100-108. PubMed ID: 38172024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expert consensus on clinical practice of EGFR exon20 insertion detection in non-small cell lung cancer in China (2024 edition)].
    Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):179-188. PubMed ID: 38494765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.
    Viteri S; Minchom A; Bazhenova L; Ou SI; Bauml JM; Shell SA; Schaffer M; Gu J; Rose JB; Curtin JC; Mahadevia P; Girard N
    Mol Oncol; 2023 Feb; 17(2):230-237. PubMed ID: 36269676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies 
in Non-small Cell Lung Cancer].
    Wang Y; Chu T
    Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):135-147. PubMed ID: 36872052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
    Yasuda H; Ichihara E; Sakakibara-Konishi J; Zenke Y; Takeuchi S; Morise M; Hotta K; Sato M; Matsumoto S; Tanimoto A; Matsuzawa R; Kiura K; Takashima Y; Yano S; Koyama J; Fukushima T; Hamamoto J; Terai H; Ikemura S; Takemura R; Goto K; Soejima K
    Lung Cancer; 2021 Dec; 162():140-146. PubMed ID: 34808485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
    Duan J; Wu L; Yang K; Zhao J; Zhao Y; Dai X; Li M; Xie Y; Yao Y; Zhao M; Zhou C; Ren X; Liu Z; Pan Y; Li Y; Liu B; Cheng Y; Miao L; Yu Q; Zhang Z; Liu X; Cui J; Zhang Y; Zhang L; Li X; Li X; Shen B; Chen B; Zeng S; Li B; Hu Y; Li L; Wu R; Song Q; Wang J
    J Thorac Oncol; 2024 Feb; 19(2):314-324. PubMed ID: 37776953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
    Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
    Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Clinical Outcomes for Patients with
    Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
    Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
    Jatkoe T; Wang S; Odegaard JI; Velasco Roth AM; Osgood D; Martinez G; Lucas P; Curtin JC; Karkera J
    J Mol Diagn; 2022 Nov; 24(11):1181-1188. PubMed ID: 35963523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.
    Chen H; Hu S; Patterson AV; Smaill JB; Ding K; Lu X
    J Med Chem; 2023 Sep; 66(17):11656-11671. PubMed ID: 37669428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
    Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
    Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.